[Skip to Navigation]
Other Articles
March 19, 1938


JAMA. 1938;110(12):901-902. doi:10.1001/jama.1938.02790120043013

Following the appearance of items in the press duringe last few weeks, many inquiries have been received concerning the use of benzedrine suflage in the treatment of obesity. Sensational reports on the effects of benzedrine sulfate are not new to the medical press or to the daily newspapers. Some months ago The Journal published a critical editorial on benzedrine sulfate.1 At that time the drug was being used unwisely to avoid fatigue; news that it could be obtained for keeping one awake while "cramming" for final examinations spread from campus to campus. The drug has been employed for such widely variable conditions as anginal pain, seasickness and apathy. Now it is suggested for weight reduction. While not as toxic as the ill famed reducing agent dinitrophenol,2 nevertheless its use may be followed by serious consequences. Just as the Council on Pharmacy and Chemistry issued a report on the status of dinitrophenol, it has recently published a report on benzeddrine sulfate.3